VERAXA Biotech AG (NASDAQ: VRXA) has transitioned to the U.S. public markets and is advancing an oncology pipeline built around its proprietary BiTAC(R) platform, marking a new phase for the Swiss biotechnology company. The company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. That transaction included financing arrangements such as a $27.5 million senior secured note and a securities purchase agreement for up to an undisclosed additional amount, according to a company update. The NASDAQ listing gives VERAXA access to U.S. public capital as it develops its therapeutic programs.
At the center of the company’s strategy is the BiTAC platform, an “AND-gated” therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated. This design is intended to increase precision by requiring dual targeting, potentially reducing off-tumor effects. VERAXA is also pursuing additional antibody-drug conjugate and engineered-antibody technologies alongside BiTAC. The company has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June. For investors and the oncology field, the progression from preclinical validation to a public-market story is significant because it provides a clearer financing path for early-stage science that has yet to enter human trials.
Recent corporate developments include the appointment of Raju Willener as chief financial officer and Christoph Erkel, Ph.D., as chief scientific officer. The additions bring financial and antibody-development expertise to the leadership team as VERAXA moves forward. The company’s newsroom at https://nnw.fm/VRXA provides ongoing updates relating to VRXA, and a more detailed account of the company’s pipeline and public-market transition is available in the original announcement at Read More>>.
The broader context of VERAXA’s move is a communications and distribution effort through NetworkNewsWire, a specialized platform focused on financial news and content distribution for private and public companies and the investment community. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. That network provides access to wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and a full array of tailored corporate communications solutions. For VERAXA, the visibility that comes with a NASDAQ ticker and an expanded communications footprint could help attract investors and partners as the company works to translate its preclinical findings into clinical programs. Full terms of use and disclaimers applicable to NetworkNewsWire content are available at https://www.NetworkNewsWire.com/Disclaimer.
